48 Results

People

  1. Horwitz
    Horwitz
  2. Palomba
    Palomba
  3. Younes
    Younes
  4. Batlevi
    Batlevi
  5. Moskowitz
    Moskowitz
  6. Matasar
    Matasar
  7. Yahalom
    Yahalom
  8. Hamlin
    Hamlin
  9. Zelenetz
    Zelenetz
  10. Dogan
    Dogan

Groups

  1. Department of Medicine (47)
  2. Hematologic Malignancies, Division of (47)
  3. Center for Hematologic Malignancies (43)
  4. Lymphoma (37)
  5. Population Sciences Research Program (12)
  6. Survivorship Research (12)
  7. Executive Committee, Center for Hematologic Malignancies (11)
  8. Epidemiology and Biostatistics (8)
  9. Adult Leukemia (7)
  10. Biostatistics Service (7)
  1. "2019"
  2. "Hematological Oncology"
Formats
  1. Meeting Abstract (45)
  2. Review (2)
  3. Conference Paper (1)
Groups
  1. Department of Medicine (47)
  2. Hematologic Malignancies, Division of (47)
  3. Center for Hematologic Malignancies (43)
  4. Lymphoma (37)
  5. Population Sciences Research Program (12)
  6. Survivorship Research (12)

More Groups

People
  1. Maria Palomba (12)
  2. Steven Horwitz (12)
  3. Anas Younes (11)
  4. Alison Moskowitz (8)
  5. Connie Batlevi (8)
  6. Joachim Yahalom (7)

More People

Years
  1. 2019 (48)
Publications
  1. Hematological Oncology (48)
Publishers
  1. Wiley Blackwell (48)

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms
    Review

    Mughal, T. I.; Pemmaraju, N.; Radich, J. P.; Deininger, M. W.; Kucine, N.; Kiladjian, J. J.; Bose, P.; Gotlib, J.; Valent, P.; Chen, C. C.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • An ongoing phase 1/1b trial investigating novel treatment regimens with mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Kim, W. S.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Budde, L. E.; Cheah, C.; Gregory, G. P.; Hong, J.; Ku, M.; Marlton, P.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A phase 1/1b dose-escalation trial evaluating CPI‐818, an oral interleukin‐2‐inducible T‐cell kinase inhibitor, in patients with relapsed/refractory T‐cell lymphoma
    Meeting Abstract

    Mobasher, M.; Miller, R.; Janc, J.; Kwei, L.; Barker, C.; Mohammady, A.; Luciano, G.; Radeski, D.; Kim, Y.; Khodadoust, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A phase 1/2 study of MT‐3724 to evaluate safety, pharmacodynamics and efficacy of MT‐3724 for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma
    Meeting Abstract

    Burnett, C. A.; Hamlin, P.; Dabovic, K.; Higgins, J.; Persky, D. O.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A pivotal, randomized, double-blind, placebo-controlled, two-arm, phase 2 study of ME‐401 investigating two dosing schedules in patients with follicular lymphoma (FL) after failure of two or more prior systemic therapies
    Meeting Abstract

    Zelenetz, A.; Zinzani, P.; Buske, C.; Ribrag, V.; Cunningham, D.; Jurczak, W.; Abrisqueta, P.; Agajanian, R.; Chaudhry, A.; Kayyal, T.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • BIANCA: A phase 2 study of the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed/refractory mature B‐cell non-Hodgkin lymphoma
    Meeting Abstract

    Minard‐Colin, V.; Burkhardt, B.; Maude, S.; Phillips, C.; Diaz de Heredia Rubio, C.; Laetsch, T. W.; Curran, K.; Newsome, S.; Murray, N.; Pacaud, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Multi‐center phase II study of oral azacitidine (CC‐486) plus CHOP as initial treatment for peripheral T‐cell lymphoma
    Meeting Abstract

    Ruan, J.; Leonard, J. P.; Coleman, M.; Rutherford, S.; Van Besien, K.; Rodriguez, A.; Benderoff, L.; Mehta‐Shah, N.; Moskowitz, A.; Sokol, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Dose finding study to assess safety, PK and efficacy of fimepinostat (CUDC‐907) with venetoclax or rituximab plus bendamustine in patients with relapsed/refractory lymphoma
    Meeting Abstract

    Younes, A.; Batlevi, C. L.; Cohen, J. B.; Kelly, K.; Landsburg, D. J.; Patel, K.; Phillips, T.; Smith, S.; Westin, J.; Ma, A. W.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Real‐world assessment of practice efficiency with the introduction of subcutaneous rituximab
    Meeting Abstract

    Matasar, M. J.; Qiu, A.; Shapouri, S.; Drill, E. N.; Schade, J.; Ravelo, A.; Ni, A.; To, T. M.; Dawson, K. L.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Grade 3A follicular lymphoma can be effectively controlled with very low dose radiation therapy
    Meeting Abstract

    Imber, B. S.; Chau, K.; Goldberg, E.; Joffe, E.; Yahalom, J.
    Hematological Oncology (2019)

    Fulltext@MSK | Save